Pure EPA Vascepa (icosapent ethyl) Showed Reductions in Potentially...

Pure EPA Vascepa (icosapent ethyl) Showed Reductions in Potentially...


Amarin Corporation plc today announced an oral presentation at the American Heart Association Scientific Sessions 2016, New Orleans on November 14, 2016 that further characterized the efficacy and safety of VascepaA in statin-treated women with persistent high triglyceride levels. The presentation of additional data from the ANCHOR study showed, consistent with overall study results, that prescription pure EPA VascepaA reduced triglyceride levels and several other potentially atherogenic lipid parameters and inflammatory markers in a subgroup of statin-treated women with persistent high triglycerides.



from Biotech News